BioInvent International

Regulatory Filings • Sep 27, 2018

BioInvent signs licensing and manufacturing agreement with CardioVax for the development of orticumab

Lund, Sweden – 27 September 2018 – BioInvent International AB (OMXS: BINV) announced today that following a global licensing agreement it has signed a manufacturing agreement with CardioVax for orticumab, previously known as BI-204. CardioVax, a privately held company in California, is advancing the treatment of inflammatory diseases with novel antibody therapeutics. Under the terms of the agreement, Bioinvent is expected to generate manufacturing revenue of approximately USD 3.0 million in the near term, mainly in 2019. Furthermore, in the longer term BioInvent is entitled to royalties on future net sales.

About BioInvent

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company's lead program BI-1206 is currently in a Phase 1/2 for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent's pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.se

For further information, please contact:

Martin Welschof, CEO	Hans Herklots, LifeSci Advisors
+46 (0)46 286 85 50	+41 79 598 71 49
martin.welschof@bioinvent.com	hherklots@lifesciadvisors.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263 Visiting address: Sölvegatan 41 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET, on 27 September, 2018.